Acid-Neutralizing Omeprazole Formulation for Rapid Release and Absorption

被引:0
作者
Ramesh, Sreela [1 ]
Zvonicek, Vit [1 ]
Pecek, Daniel [1 ]
Pislova, Marketa [1 ]
Beranek, Josef [1 ]
Hofmann, Jiri [1 ]
Dumicic, Aleksandra [1 ]
机构
[1] Zentiva Ks, U Kabelovny 130, Prague 10237, Czech Republic
关键词
omeprazole; neutralization; absorption; pharmacokinetics; stability; drug release;
D O I
10.3390/pharmaceutics17020161
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background/Objectives: Omeprazole undergoes degradation in acidic conditions, which makes it unstable in low pHs found in the gastric environment. The vast majority of already marketed omeprazole formulations use enteric polymer coatings to protect the drug from exposure to acidic pH in the stomach, allowing for drug release in the small intestine where the pH is higher. This study aimed to explore the technical aspects of using stomach acid neutralizers as an alternative to polymeric coatings for omeprazole. Methods: After evaluating various neutralizers, magnesium oxide and sodium bicarbonate were chosen to be incorporated into capsules containing omeprazole, which then underwent in vitro dissolution testing to assess their ability to maintain optimal pH levels and ensure appropriate dissolution kinetics. Hygroscopicity and chemical stability of the selected formulation were tested to prove pharmaceutical quality of the product. An in vivo pharmacokinetic study was conducted to demonstrate the efficacy of the omeprazole-sodium bicarbonate formulation in providing faster absorption in humans. Results: Sodium bicarbonate was selected as the most suitable antacid for ensuring omeprazole stabilization. Its quantity was optimized to effectively neutralize stomach acid, facilitating the rapid release and absorption of omeprazole. In vitro studies demonstrated the ability of the formulation to neutralize gastric acid within five minutes. In vivo studies indicated that maximum concentrations of omeprazole were achieved within half an hour. The product met the requirements of pharmaceutical quality. Conclusions: An easily manufacturable, fast-absorbing oral formulation was developed as an alternative to enteric-coated omeprazole.
引用
收藏
页数:12
相关论文
共 26 条
  • [1] Epidemiology of gastrooesophageal reflux disease: A systematic review
    Dent, J
    El-Serag, HB
    Wallander, MA
    Johansson, S
    [J]. GUT, 2005, 54 (05) : 710 - 717
  • [2] Elliott R., 1998, Aust. J. Hosp. Pharm, V28, P174, DOI [10.1002/jppr1998283174, DOI 10.1002/JPPR1998283174]
  • [3] European Medicines Agency, CPMP/QWP/122/02
  • [4] European Pharmacopoeia (Ph. Eur.), About us
  • [5] Gastro-oesophageal reflux disease
    Fass, Ronnie
    Boeckxstaens, Guy E.
    El-Serag, Hashem
    Rosen, Rachel
    Sifrim, Daniel
    Vaezi, Michael F.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2021, 7 (01)
  • [6] Antacids revisited: review on contemporary facts and relevance for self-management
    Garg, Vandana
    Narang, Prashant
    Taneja, Ritu
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (03)
  • [7] Similarities and differences among delayed-release proton-pump inhibitor formulations
    Horn, JR
    Howden, CW
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 : 20 - 24
  • [8] Japan Medical Safety Investigation Agency medsafe, About us
  • [9] ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease
    Katz, Philip O.
    Dunbar, Kerry B.
    Schnoll-Sussman, Felice H.
    Greer, Katarina B.
    Yadlapati, Rena
    Spechler, Stuart Jon
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (01) : 27 - 56
  • [10] The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
    Kim, Dasohm
    Park, Min Soo
    Yoo, Byung Won
    Hong, Taegon
    Park, Shin Jung
    Kim, Choon Ok
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 3151 - 3159